In Brief: MiniMed
This article was originally published in The Gray Sheet
Executive SummaryMiniMed: Continuous subcutaneous glucose sensor 510(k) submitted to FDA, the company reports Dec. 17. MiniMed told the UBS Life Sciences conference in October that its 60-patient pivotal trial for the electrochemical-based sensor technology was in final stages and that a 510(k) for a "holter-style" glucose monitor would be submitted by year-end ("The Gray Sheet" Oct. 20, I&W-3). The company says it hopes to develop a series of products from the technology, including a hyper/hypo-glycemic alarm device, a 510(k) for which is expected to be submitted in early 1998...
You may also be interested in...
At the OurCrowd Global Investor Summit in Jerusalem, Israel, on 13 February, Medtech Insight met wound care device company Nanomedic to find out more about its unique electro-spinning technology.
At the OurCrowd Global Investor Summit, in Jerusalem, Israel, on 13 February, Medtech Insight met with start-up Sweetch, which has developed a personalized digital health coach for wellness and disease management.
Medtech Insight attended the OurCrowd Global Investor Summit in Jerusalem on February 13. At the meeting, Ofer Barnea, CEO of neurosurgery start-up SynCath Neuroscience, explained his company’s device to treat cerebral edema,